Viskase Holdings, Inc.
Viskase Holdings, Inc., currently Enzon Pharmaceuticals, Inc., is a public company acquisition vehicle with no employees and no clinical operations for more than ten years. Its executive officer provides services on a consulting basis. Historically, the company received royalties from licensing arrangements involving drug products that used its proprietary technology, and it has licensing agreements regarding SC Oncaspar and certain other drugs. It no longer receives royalties from PegIntron and its Vicineum license was canceled in 2025. Enzon has agreed to merge its wholly owned subsidiary EPSC Acquisition Corp. with Viskase Companies, Inc., with Viskase surviving as a wholly owned subsidiary. The merger remains subject to satisfaction or waiver of the remaining closing conditions. If completed, Enzon will change its name to Viskase Holdings, Inc. The company is based in Lombard, Illinois.
No SEC Form 4 filings for $VISK in the last 30 days.
See all $VISK insider activity →Viskase Holdings reported 3Q 2026 revenue of $95.28M, up 4.5% YoY, with a net loss of $6.4M, improved from $12.98M YoY. EPS loss was $0.45, better than $2.4 a year earlier. Sales growth was driven by higher volume, pricing, and product mix, while nine-month sales declined 3.8% due to lower volume and capacity constraints.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VISK (Viskase Holdings, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
The modest revenue growth and loss narrowing may provide slight upside potential if investors view the turnaround positively.
AlphAI scores every news story that mentions VISK with an AI model for sentiment and relevance, and aggregates insider trades from Viskase Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Viskase Holdings reported 3Q 2026 revenue of $95.28M, up 4.5% YoY, with a net loss of $6.4M, improved from $12.98M YoY. EPS loss was $0.45, better than $2.4 a year earlier. Sales growth was driven by higher volume, pricing, and product mix, while nine-month sales declined 3.8% due to lower volume and capacity constraints.
1 min read
